have been withdrawn in bladdercancer as a result. Gilead said Trodelvy’s safety profile in the TROPHY study is consistent with previous observations in metastatic UC and other tumour types.
Data Span Multiple Types of Lung Cancer and Lines of Therapy- FOSTER CITY, Calif., September 05, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company ...
notably triple-negative breast and bladdercancer therapy Trodelvy (sacituzumab govitecan), which Gilead acquired as part of its $21 billion takeover of Immunomedics in 2020. Two of the three ...
Some results have been hidden because they may be inaccessible to you